<DOC>
	<DOCNO>NCT00160433</DOCNO>
	<brief_summary>The objective study determine safety efficacy 3 asoprisnil dos ( 0.5 mg , 1.5 mg , 5.0 mg ) 12 week woman endometriosis .</brief_summary>
	<brief_title>A Study Evaluate Safety Effectiveness Asoprisnil Treatment Women With Endometriosis .</brief_title>
	<detailed_description>Endometriosis , presence endometrial tissue outside uterus , progressive , estrogen-dependent disease occur menstruate woman reproductive age . Although major endometriosis therapy effective treatment pain , single treatment superior others term efficacy . The major drawback current medical therapy severe side effect hot flush osteoporosis . The objective study determine dose-response relationship exist asoprisnil endometriosis-associated pelvic pain dysmenorrhea establish low effective dose asoprisnil treatment pelvic pain dysmenorrhea associate endometriosis . Women surgically confirm endometriosis administer asoprisnil 0.5 , 1.5 , 5 mg tablet placebo daily 3 month efficacy assess improvement pelvic pain , dysmenorrhea , dyspareunia , bleeding , analgesic use , global efficacy , quality life questionnaire . Safety base assessment endometrium , lipid profile , adverse event , change baseline laboratory value vital sign .</detailed_description>
	<mesh_term>Endometriosis</mesh_term>
	<criteria>Premenopausal woman ( 1840 year ) Surgically confirm endometriosis within 3 year History menstrual cycle 21 35 day Moderate severe pelvic pain OR moderate severe dysmenorrhea OR moderate severe pelvic tenderness accompany least mild nonmenstrual pelvic pain Negative pregnancy test Agrees use double barrier method contraception Pap smear evidence malignancy premalignant change Ultrasound significant gynecological disorder . Otherwise good health Less 3 month baby breastfeed Any abnormal lab procedure result studydoctor considers important Severe reaction ( ) hormone therapy Anticipated need exclude hormonal therapy unapproved narcotic Current use IUD History prolactinoma</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>Pelvic pain</keyword>
	<keyword>Dysmenorrhea</keyword>
	<keyword>Dyspareunia</keyword>
	<keyword>Infertility</keyword>
	<keyword>asoprisnil</keyword>
</DOC>